Hundreds of entries were judged by a panel of recognized industry experts, media and analysts and scored on innovation, functionality, technological importance, implementation and overall "wow" factor.
"We are honored iglucose was chosen as a finalist among entries from much larger companies including Alcatel-Lucent, AT&T, HTC, Motorola, Nokia Siemens, Samsung, Qualcomm and others," stated Mary Ellen Harrison, Vice President of Health ID at PositiveID.
Simplicity sets iglucose apart from other mobile health solutions. iglucose can be used by consumers of any technical skill level. It is easy to use and conveniently fits within a pocket or purse. Usability tests conducted as part of the iglucose FDA review process demonstrated 100 percent of consumers were able to use the device regardless of their age. After initial enrollment there are no technology requirements for the end user. Consumers simply connect their glucometer to iglucose and push a button. The iglucose system creates a variety of reports and communicates according to each individual's preferences via online access, email, fax or SMS text.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. Family members have greater peace of mind; now parents of children with diabetes can receive text messages to let them know their children are testing while at school. iglucose does not require the use of a cell phone or a wireless plan.
Between now and May 8, website visitors may vote for the "Best Online Pick" at www.ctiashow.com/awards. International CTIA WIRELESS show attendees will vote onsite via text message for entries in the E-Tech Awards showcase in Booth 4575 at the Emerging Technology Zone to win "Best in Show."
To vote for iglucose visit http://ctiait.ctia.org/etech/2012/public/index.cfm/viewEntry/617. To learn more about iglucose visit www.iglucose.com or email info@iglucose.com.
For more information on the E-Tech Awards, visit www.ctiashows.com/awards.
For additional details and a comprehensive look at the CTIA conference program, visit: www.ctiawireless.com. Members of the media may pre-register for full access to all show events at: www.ctiashows.com/pressreg.
Follow CTIA Shows:
Facebook: www.ctiashows.com/facebook
LinkedIn: www.ctiashows.com/linkedin
Twitter: www.ctiashows.com/twitter (#CTIAW12)
About CTIA Shows
CTIA Shows bring together all industries advanced by wireless technology for intense business, learning and networking. International CTIA WIRELESS(R) takes place May 8-10, 2012 at the Ernest N. Morial Convention Center in New Orleans, La. CTIA ENTERPRISE & APPLICATIONS(TM) takes place Oct. 9-11, 2012 at the San Diego Convention Center in San Diego, Calif. Visit www.ctiashows.com.
About CTIA
CTIA--The Wireless Association(R) (www.ctia.org) is an international organization representing the wireless communications industry. Membership in the association includes wireless carriers and their suppliers, as well as providers and manufacturers of wireless data services and products. CTIA advocates on behalf of its members at all levels of government. The association also coordinates the industry's voluntary best practices and initiatives, and sponsors the industry's leading wireless tradeshows. CTIA was founded in 1984 and is based in Washington, D.C.
The CTIA Wireless Association logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12582
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do
not make recommendations. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. We attempt
to research thoroughly, but we offer no guarantees as to the accuracy
of information presented. All Information relating to featured companies
is sourced from public documents and/ or the company and is not the
opinion of our web sites. This site is currently compensated by featured
companies, news submissions and online advertising. PositiveID
Corporation (OTCBB:PSID)
featured biotech company on Investorideas.com for 3 months effective
January 30,2012 . Compensation: two hundred fifty thousand 144 shares
for news release publication, syndication on blogs and related sites and
email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.aspVisit the company profile: http://www.investorideas.com/CO/PSID/
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
No comments:
Post a Comment